Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease
NCT ID: NCT03594656
Last Updated: 2021-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
288 participants
INTERVENTIONAL
2018-07-15
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease
NCT00224263
The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease
NCT04428983
Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease
NCT00656253
Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease
NCT00629161
Clinical Research on Stem Cell Therapy for Parkinson's Disease
NCT07232147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early-start Group
Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
Ganoderma
0.8g twice daily
Delayed-start Group
Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
Ganoderma
0.8g twice daily
Placebos
0.8g twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ganoderma
0.8g twice daily
Placebos
0.8g twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 30-80 years
* Hoehn-Yahr Stageā¤2
* UPDRS Part III subscores ranging from 10 to 30 points
* Disease duration of 5 years or less
* Untreated with antiparkinsonian drugs for at least two weeks preceding the trial
* Willing to sign the written informed consent
Exclusion Criteria
* With psychiatric symptoms or a history of psychiatric diseases
* With cognitive impairment(MMSE score\<24)
* Major liver or kidney dysfunction
* Participating in other clinical trials within 3 months preceding the current trial
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erhe Xu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital of Capital Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017YFC1310202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.